Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Abatacept (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 23 Jan 2018 Planned number of patients changed from 10 to 25.
- 23 Jan 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 23 Jan 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.